DBP.B: Losses narrowed as SI-053 advanced; funding secured, liquidity sufficient into Q3 2025

About this update from Double Bond Pharmaceutical International Ab Class B

Double Bond Pharmaceutical reduced losses in 2024 while advancing SI-053 toward clinical trials, securing new financing, and optimizing manufacturing. Liquidity is expected to last until Q3 2025, with further funding planned from grants and partnerships.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Double Bond Pharmaceutical International Ab Class B